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Abstract 
Objective: While several studies have reported on the relation of diabetes status 
with pancreatic cancer risk, the predictive value of this disorder for other 
malignancies is unclear.   
Methods: The Whitehall study, a 25 year follow-up for mortality experience of 
18,006 men with data on post-challenge blood glucose and self-reported 
diabetes, allowed us to address these issues.   
Results: There were 2158 cancer deaths at follow-up.  Of the fifteen cancer 
outcomes, diabetes status was positively associated with mortality from 
carcinoma of the pancreas and liver, while the relationship with lung cancer 
was inverse, after controlling for a range of potential covariates and mediators 
which included obesity and socioeconomic position.  After excluding deaths 
occurring in the first 10 years of follow-up to examine the effect of reverse 
causality, the magnitude of the relationships for carcinoma of the pancreas and 
lung was little altered, while for liver cancer it was markedly attenuated.    
Conclusions: In the present study, diabetes status was related to pancreatic, 
liver and lung cancer risk.  Cohorts with serially collected data on blood 
glucose and covariates are required to further examine this area. 
  
Keywords: blood glucose, cancer, diabetes, cohort study
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Introduction 
An unexpectedly high prevalence of hyperglycaemia in cancer patients was first 
described over a century ago.1;2  However, it is only in the last two decades that 
population-based cohort studies – largely established to identify risk factors for 
cardiovascular disease – have accumulated sufficient cancer cases to allow an 
examination of the role of diabetes, assessed prior to cancer presentation, in the 
development of this condition.  While an excess of total cancer cases is seen in 
some,3-6 but not all,7-9 diabetes groups, the pattern of association is most 
consistent for pancreatic cancer.10-13  Mechanisms advanced to explain the 
diabetes-pancreatic cancer relationship include the carcinogenesis-stimulating 
effects of insulin – the so called ‘insulin hypothesis’ – and the activation of 
insulin-like-growth-factor 1 (IGF-1) receptor which enhances pancreatic cell 
proliferation.14   Although IGF-1 has also been implicated in the aetiology of 
colorectal and prostate malignancies,15 the association of diabetes with these 
malignancies, amongst others, has not been extensively examined.     
 
In addition to this limited evidence base, interpretation of results from many 
existing studies is hampered by one or more of the following methodological 
limitations.  Firstly, that diabetes status is poorly characterised, with most 
investigators relying on self-reports of physician diagnoses rather than direct 
blood glucose measurement, leads to misclassification of this exposure.  
Secondly, for some cancers (e.g., pancreatic), it has been postulated that 
diabetes is a clinical manifestation of occult malignancy,16 raising concerns 
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about reverse causality.10  Thirdly, confounding by characteristics such as 
obesity and socioeconomic position – predictors of both diabetes and cancer 
risk – may be an alternative explanation for some of the associations seen.  
Finally, a focus in many reports on a single malignant neoplasm as the endpoint 
of interest, rather than a range, limits insights into specificity of association – an 
important criteria in the assessment of causation in observational studies.17   
 
In the present study, we report on the relation of diabetes status and post-load 
plasma glucose with cancer mortality in a follow-up of 18,403 male British 
government employees.  In this cohort, the measurement of fasting post-
challenge blood glucose in addition to self-reported diabetes status; the 
assessment of potential confounding variables including overweight and 
socioeconomic position; the high number of cases – the cohort has accumulated 
in excess of two thousand cancer deaths over 25 years of surveillance; and 
analyses across a number of cancer sites, allows us to address the 
aforementioned shortcomings.  This report extends considerably earlier findings 
from the Whitehall study7 by reporting on a later follow-up with many more 
cancer deaths and therefore a greater range of site-specific outcomes.  
 
Materials and Methods 
Study participants 
In the Whitehall study, data were collected on 18,403 non-industrial London-
based male government employees aged from 40 to 64 yr. when examined 
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between September 1967 and January 1970, representing a 74% response 
proportion.  Data collection involved the completion of a study questionnaire 
and participation in a medical examination, both of which have been described 
in detail elsewhere.18  In brief, the questionnaire included enquiries regarding 
civil service employment grade (an indicator of socio-economic position),19;20 
smoking habits,21 intermittent claudication,22;23 angina,22;24 chronic bronchitis,25 
and physical activity while travelling to work26 and during leisure time.27;28   
Forced expiratory volume in one second (FEV1) (adjusted for height27), 
ischaemia,29 fasting plasma cholesterol,30 two-hour blood glucose,31 blood 
pressure,32 height,33 and weight34 were determined using standardised protocols.   
 
Assessment of diabetes status and plasma glucose level 
Each man was requested to fast from the night before the medical examination 
which was held in the morning.   Capillary blood samples were drawn from the 
ear lobe two hours after participants drank a glucose preparation equivalent to 
50g of anhydrous dextrose (‘Lucozade’ drink).   From these samples, blood 
sugar concentration was estimated using the ferricyanide reduction 
micromethod on an autoanalyser (Technicon method N-9a).   Study participants 
were categorised into three groups based on data from the questionnaire and the 
post-load blood glucose test:7;27 35 (1) Men with diabetes:  a positive response to 
the questionnaire enquiry  “are you, or have you been, diabetic?” or, blood 
glucose level two hours after the glucose load of ≥11.1 mmol/l (≥200 
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mg/100ml); (2) Men with impaired glucose tolerance: blood glucose of 5.4 to 
11.0 mmol/l (96 to 199 mg/100ml); (3) Normoglycaemic men: all remaining 
subjects.   Furthermore, blood glucose results in the normoglycaemic group 
were sub-divided into quartiles: ≤ 66; 67-73; 74-79; 80-95 mg/100ml.7 
  
Mortality  ascertainment 
Records from 18,260 men (99.2% of the 18,403 eligible) were traced and 
flagged at the National Health Service Central Registry, representing an almost 
complete 25 years follow-up until 31st January 1995.  Death certificates were 
coded according to the eighth revision of the International Classification of 
Diseases (ICD).36  Mortality was classified as being due to all malignant 
neoplasms (ICD 140-208) – referred to here as ‘all-cancers’.  This group was 
sub-divided into thirteen individual sites: oesophagus (ICD 150); stomach (ICD 
151); colon (ICD 153); rectum (ICD 154); liver (ICD 155-156); pancreas (ICD 
157); trachea, bronchus and lung (ICD 162 – referred to as ‘lung cancer’); 
prostate (ICD 185); bladder (ICD 188); kidney (ICD 189); brain (ICD 191); 
lymphoma (ICD 200-203); and leukaemia (ICD 204-207).  ‘Other’ cancer 
comprised deaths due to malignancies occurring at sites other than the 
aforementioned. 
 
Statistical analyses 
Employment grade was categorised as administrative, professional or 
executive, clerical, and "other grades" (men in messenger and other unskilled 
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manual jobs).  For 873 men from the Diplomatic Service and the British 
Council, employment grade was not comparable to the rest of the sample and 
they have been classified as a separate group.  Smoking was classified 
according to cigarette use as ‘current smoker’, ‘ex-smoker’ and ‘never smoker’.  
The 378 men who smoked pipes or cigars only have been included as a separate 
group in the analyses that involve smoking status.  During the baseline study, 
the physical activity enquiries on the questionnaire were modified.  Levels of 
this behaviour were therefore determined from either an item about travel 
activity26 (administered to approximately two-thirds of men) or from leisure 
activities28 (administered to the remainder).  Existing disease at entry to the 
study was defined as a positive response to enquiries regarding intermittent 
claudication, physician-diagnosed heart problems or high blood pressure (one 
question), dyspnoea, and bronchitis.  The existence of ischaemia was 
determined from ischaemic signs on an ECG trace, or positive responses to 
either the Rose angina questionnaire, or a report of severe pain across the front 
of the chest lasting half and hour or more.24 
 
Among the 18,260 men who were successfully traced, 870 men had some 
missing data for one or more of the following variables:  self-reported diabetes 
or plasma blood glucose (128 men), physical activity (38), blood pressure-
lowering medication (10), marital status (4), systolic blood pressure (6), 
cholesterol (679), body mass index (3), height (3), FEV1 (12), triceps skinfold 
thickness (24), and smoking status (4).  To clarify data interpretation, the 46 
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men who reported that their diabetes was controlled by insulin medication were 
excluded to ensure that only men with type 2 diabetes were present in the 
analyses.  We also excluded 26 men because of missing information as to their 
cause of death.  In order to maximise the number of men in the analysis, the 
few with missing data values for continuous measures only (listed below) were 
retained in the mortality analyses and multiple imputation used to produce 
values for these missing measures.  Thus, five datasets with imputed measures 
were generated and the regression estimates from the analysis of these were 
averaged.37  The final number of men upon which all the cancer mortality 
analyses were based was 18,006. 
 
 
In analyses of baseline characteristics according to diabetes status, their 
prevalence was adjusted for age (5 year age groups) by the direct 
standardisation method.  Trends in these proportions were tested for statistical 
significance using the Mantel-Haenszel test.   For baseline characteristics 
expressed as continuous variables, least squares means were used to present the 
age-adjusted means and tests for trend across diabetes groups were computed 
by fitting a linear trend term.   
 
Models fitted with a plasma blood glucose by follow-up time interaction term 
confirmed that the proportional hazards assumption was not violated.  Thus, 
hazard ratios and accompanying confidence intervals were computed for the 
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relation of diabetes and blood glucose level with each mortality outcome using 
Cox's proportional hazards regression model38 with follow-up period as the 
time scale.   Using this technique we conducted three separate analyses.  First, 
the relation of diabetes and impaired glucose tolerance with cancer mortality 
was examined using the normoglycaemic group as the referent category. 
Second, in the sub-group of men who were designated normoglycaemic, we 
explored the association across quartiles of blood glucose with cancer mortality 
using the lowest quartile as the referent category.  Third, in the 
normoglycaemic group, the association of a one standard deviation (9.57 
mg/100ml) increase in blood glucose with cancer mortality was assessed.    
 
These models were initially adjusted for age and then for other potential 
confounding (employment grade, smoking status, physical activity, systolic 
blood pressure, blood pressure-lowering medication, marital status, disease at 
study entry, unexplained weight loss) and mediating (body mass index, triceps 
skinfold thickness, height-adjusted FEV1, plasma cholesterol) variables.  Of 
these, age, plasma cholesterol, systolic blood pressure, body mass index, triceps 
skinfold thickness, and height-adjusted FEV1 were fitted as continuous 
variables, whereas employment grade (5 levels), marital status (4), physical 
activity (6), blood pressure lowering medication (2), smoking status (4) (with 
additional adjustment for the number of cigarettes smoked per day in current 
smokers), unexplained weight loss in the past year (2) and disease at entry (2) 
were fitted as categorical variables.  Tests for trend in mortality rates across 
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diabetes groups were again computed by fitting a linear trend term. 
 
To address the issue of reverse causality – as discussed, for some cancers 
tumour presence may increase elevate blood glucose levels so generating a 
positive blood glucose–cancer association10 – we excluded deaths in the first 10 
years of mortality surveillance and repeated our analyses.  In so doing, we 
reasoned that a large proportion of deaths attributable to cancer, if present at 
study induction, would have occurred within this time frame.39    All statistical 
analyses were computed using SAS computer software.40  
 
 
Results 
In table 1 the relationship of each study covariate with diabetes status in all 
study participants and with blood glucose in the sub-group who were 
normoglycaemic are presented.  In the former analysis, the most favourable 
levels of each baseline characteristic were generally seen in persons who had 
normal levels of blood sugar: these men were younger, taller, leaner, had lower 
systolic blood pressure and higher pulmonary function than those with diabetes 
or IGT.  They were also less likely to be of low employment grade, be without 
a partner, and report recent weight loss or carry a morbid load.  In contrast, the 
prevalence of cigarette smoking was lowest in the IGT and diabetes groups.  In 
men classified as normoglycaemic, the relationship between blood glucose and 
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covariate data was similar to some of those seen in the afore mentioned 
analysis.  
 
After 25 years follow-up there were 2158 cancer deaths in this cohort.  In Table 
2 the relation between diabetic status and fifteen cancer mortality outcomes is 
depicted.  Most of the cancer mortality endpoints were unrelated to diabetes 
status.  Three associations at conventional levels of statistical significance 
emerged in multiply-adjusted analyses: both cancer of the pancreas (HRdiabetes vs 
normoglycaemic; 95% confidence interval:  3.99; 1.44, 11.0; Ptrend=0.02) and liver 
(9.22; 2.66, 31.9; Ptrend=0.001) were positively and incrementally associated 
with diabetes status, while the relation with lung cancer was inverse (0.31; 0.08, 
1.24; Ptrend=0.06).    Bladder cancer rates were also raised in the IGT group 
(HRIGT vs normoglycaemic; 95% confidence interval:  2.19; 1.16, 4.16; 
Pdifference=0.02); but the trend across the three diabetes status groups was non-
significant (P=0.15).   
 
When we excluded deaths in the first ten years of follow-up to explore the issue 
of reverse causality (table 3) the attenuation of risk for liver cancer was marked 
(4.74; 0.59, 37.9) but less pronounced for carcinoma of the pancreas (3.34; 
0.81, 13.8) and lung (0.54; 0.13, 2.16).  Given the low number of cases on 
which these analyses are based – there was only one liver cancer case in the 
diabetes group, for instance – and the accompanying statistical imprecision, 
some of these results should be viewed with caution.   
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When we examined the relation of blood glucose to cancer mortality experience 
in men who were classified as normoglycaemic there was a suggestion of a 
positive association between liver cancer and blood glucose, however, 
statistical significance was not attained when this or any other cancer sub-types 
were the outcomes of interest (data not shown).   Essentially the same null 
associations were apparent when we excluded deaths occurring in the first 10 
years of follow-up (data not shown).   
 
Discussion 
In this study we related diabetes status and blood glucose level to fifteen cancer 
mortality endpoints in a large cohort of British male government employees.  
The main findings were that mortality from cancer of the pancreas and liver 
were positively and incrementally related to diabetes status, while the 
association with lung cancer was in the opposite direction.  On excluding deaths 
in the first 10 years of mortality surveillance, there was some attenuation of risk 
for liver cancer, although the number of deaths was small and confidence 
intervals wide.  In the subgroup of men who were classified as 
normoglycaemic, blood glucose was essentially unrelated to any of the cancer 
endpoints featured in our analyses.  
 
A decade ago some of us reported on findings from an earlier (19 yr.) follow-up 
of Whitehall study participants7 to respond the suggestion in one of the few 
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other cohort studies with measured blood glucose levels3 that diabetes and 
impaired glucose tolerance were related to cancer risk.  Although there was no 
evidence of an effect of diabetes status on most of the ten cancer endpoints 
featured in that analyses, diabetes status was weakly related to rates of lung 
cancer and, more strongly, pancreatic cancer, in the same directions as in the 
present analysis.  At this earlier stage of follow-up there were insufficient liver 
cancer deaths to examine the predictive capacity of diabetes status for this 
condition as we have herein.    
 
Alternative explanations   
Pancreatic cancer is the malignancy most commonly linked with diabetes.  The 
finding in several studies11-13;41 of an elevated risk of this malignancy in 
diabetic groups has been attributed to reverse causality,42 such that existing but 
clinically undetected carcinoma at study induction leads to elevated blood 
glucose levels.  That a high proportion of pancreatic cancer patients reportedly 
present with diabetes or IGT,16;43 and partial pancreatectomy in a small group of 
cancer patients had a normalising effect on blood glucose levels,44 provides 
some support for this assertion.  To examine the role of reverse causality in the 
diabetes–pancreatic cancer relation, we excluded those deaths occurring in the 
first 10 years of mortality surveillance (table 3), following which the positive 
relationship was of similar magnitude.   In a comprehensive meta-analysis,10 all 
of the eight cohort studies reviewed (we exclude an earlier follow-up7 of the 
present investigation) reported a positive diabetes–pancreatic cancer relation, 
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although statistical significance was not seen in three of these.   Additionally, 
with few exceptions,45 reports appearing subsequently show statistically 
elevated rates of pancreatic carcinoma in the high blood glucose or diabetes 
groups4;45-49  
 
In comparison with the evidence base for pancreatic cancer, reports of the 
relationship between diabetes and liver cancer are more sparse.  In those 
conducted, an elevated risk of liver cancer has been reported in populations 
drawn from Italy,50 Sweden,51 Denmark,4 the US,52 and Japan.53   In the present 
UK-based study population we made the same observation.  Although the 
magnitude of this relationship was noticeably weaker after we excluded deaths 
in the first decade of mortality surveillance, this analysis was based on few 
events.   
 
In all our analyses, effect estimates were adjusted for several important 
confounding or mediating variables, including overweight and socioeconomic 
position.  Another important covariate may be alcohol consumption.54  In a 
randomly selected subgroup of study participants in the Whitehall study we 
have information on diet, including patterns of alcohol use.55 Although there 
were too few cancers in this group (176 cancer deaths in 1,658 men) to 
facilitate site-specific analyses by alcohol use, that there was no difference in 
alcohol consumption levels across the diabetes categories suggests that this 
behaviour does not have a confounding role at least in the present study.  
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Rates of lung cancer were lower in persons with diabetes and IGT.  The same 
observation has been made elsewhere,56-58 although this is not a universal 
finding.4;6;8  The apparent protective effect of diabetes has been most commonly 
ascribed to the generally lower prevalence of smoking – a powerful predictor of 
lung cancer risk – in people with diabetes in comparison to individuals without 
this condition.  However, there was a modest difference (3.5%) in cigarette 
smoking prevalence between the diabetes and normoglycaemics groups at 
baseline (table 1), probably too small to completely account for the marked 
disparity in lung cancer death rates 25 years later.   Over the period of mortality 
surveillance, it may be that these differences in smoking patterns between the 
diabetes and non-diabetes groups were further accentuated due the more intense 
scrutinisation of lifestyle that persons with this condition – presumably some 
following diagnosis in the present study – would have received from their 
diabetologists.  Survivors from the original Whitehall study have recently been 
mailed a follow-up questionnaire with enquiries about current smoking habits.59 
However, when smoking status at baseline and follow-up were stratified by 
diabetes status (diabetes, IGT and normoglycaemia), there were too few 
observations to test this hypothesis (Elizabeth Breeze, 2004 – personal 
communication).    
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Plausible mechanisms of effect 
The most frequently advanced mechanism linking blood glucose with cancer of 
the pancreas and liver is the so called ‘insulin hypothesis’.  Thus, in vitro, 
insulin seems to stimulate carcinogenesis in these organs.60 61 In addition, high 
concentrations of insulin activate insulin-like-growth-factor 1 (IGF-1) 
receptors, which in turn have been demonstrated to enhance pancreatic cell 
proliferation.14  However, although IGF-1 has also been implicated in the 
aetiology of colorectal and prostate malignancies,15 there was no relationship 
between these cancers and diabetes in the present investigation.  It is also 
plausible that the medication used to treat diabetes may precipitate some 
cancers.  Such an explanation requires investigation.   
 
Study strengths and limitations 
The strengths of the present study include its almost complete follow-up for 
mortality experience, so minimising any potential bias due to selection; the 
availability of data on a range of potential covariates and mediators, including 
socioeconomic position and adiposity; extended follow-up, so facilitating 
examination of reverse causality; and a cohort well characterised for diabetes 
owing to the assessment of both self-reported diabetes and blood glucose levels.  
However, while blood glucose was assessed objectively, in having only a single 
baseline measurement there will have been some misclassification of 
measurement at baseline.  Further misclassification will occur as the population 
ages and participants go on to develop IGT and diabetes.  Both these factors are 
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likely to lead to a conservative estimation of cancer risk.  In the present 
investigation, as in earlier reports from the Whitehall study,35;62;63 there was 
clear evidence of an association of blood glucose with total and cardiovascular 
disease mortality (HRdiabetics vs. normoglycaemics; 95% CI: 2.00; 1.54, 2.60).  Because 
this has been demonstrated in several other populations,64;65 it appears that the 
predictive validity of the blood glucose data is high.   Additionally, diabetes 
status was associated with some covariates in the expected directions 
suggesting some concurrent validity.  Finally, given that the relation of diabetes 
status with fifteen cancer outcomes was examined – necessarily conducting 
multiple tests – it is highly plausible that some the associations found herein 
could have been identified by chance.  
 
In conclusion, in this large scale prospective study offering in excess of two 
thousand cancer deaths, measured blood glucose levels and self-reported 
diabetes were unrelated to most of the fifteen cancer endpoints we examined.  
There was evidence of a positive relation of diabetes status with carcinoma of 
liver and pancreas, and the association with lung cancer was inverse.  Further 
studies which hold data on serially administered blood glucose measurements 
and cancer outcomes are required.    
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Table 1. Association between diabetes status, blood glucose and baseline characteristicsa in the Whitehall study 
 
  Diabetes status P-value
for trend 
 Quartiles of blood glucose 
(normoglycaemics) 
 
P-value 
for trend 
Normo-
glycaemic 
IGT NIDDM Quartile 1
(lowest) 
Quartile 2 
 
Quartile 3 
 
Quartile 4  
  
Numberb      16,843 975 188 4299 4231 3813 4500
                                                                                                  Mean (standard error) 
     
Age 51.4  (0.1) 53.1  (0.2) 55.8  (0.4) 0.001 51.8  (0.1) 51.4  (0.1) 51.2  (0.1) 51.2  (0.1) 0.001 
Tricep skinfold thickness (mm) 44.6  (0.1) 45.1  (0.5) 43.1 (1.2) 0.87 45.0  (0.2) 44.8  (0.2) 44.3  (0.3) 44.4  (0.2) 0.04 
Body mass index (kg/m2) 24.7  (0.02) 25.2   (0.1) 25.7  (0.2) 0.001 24.6  (0.4) 24.7  (0.4) 24.7  (0.5) 24.8  (0.4) 0.003 
Plasma cholesterol (mmol/l) 5.11  (0.01) 5.06  (0.04) 5.15  (0.09) 0.44 5.06  (0.2) 5.10  (0.2) 5.13  (0.2) 5.15  (0.2) 0.001 
FEV1c (l/sec) 3.13  (0.01) 3.05  (0.02) 2.98  (0.04) 0.001 3.12  (0.01) 3.15  (0.01) 3.15  (0.01) 3.14  (0.01) 0.11 
Systolic BP (mmHg) 135.6  (0.2) 141.5  (0.7) 138.7  (1.5) 0.001 133.8  (0.3) 135.0  (0.3) 135.8  (0.3) 137.3  (0.3) 0.001 
Height (cm) 176.0   (0.1) 174.8   (0.2) 173.8  (0.5) 0.001 175.4  (0.1) 176.2  (0.1) 176.3  (0.1) 176.1  (0.1) 0.001 
  
                                                                                                Percent (standard error) 
Inactive / zero travel time 16.0  (0.3) 15.1  (1.2) 21.6  (3.6) 0.53 19.3  (0.6) 16.2  (0.6) 14.4  (0.6) 14.1  (0.5) 0.001 
Weight loss in last yr 2.1  (0.1) 1.6  (0.4) 8.6  (2.6) 0.08 2.5  (0.2) 2.2   (0.2) 1.7  (0.2) 2.2  (0.2) 0.25 
Current cigarette smoker 41.5  (0.4) 40.5  (1.6) 37.9  (4.3) 0.06 45.0  (0.8) 41.2  (0.8) 40.3  (0.8) 39.4  (0.7) 0.001 
Low work grade 23.3  (0.3) 28.4  (1.4) 39.9  (4.0) 0.001 22.9  (0.6) 23.0  (0.6) 22.9  (0.7) 24.2  (0.6) 0.18 
No partner 11.5   (0.3) 14.5  (1.2) 19.6  (3.5) 0.001 11.7  (0.5) 11.1  (0.5) 10.9  (0.5) 12.2  (0.5) 0.52 
Disease at study entryd  20.2  (0.3) 27.9  (1.4) 23.1  (3.4) 0.001 20.2  (0.6) 20.7  (0.6) 20.7  (0.7) 19.4  (0.6) 0.32 
Blood pressure-lowering 
medication 
1.5  (0.1) 2.4  (0.5) 1.2  (0.6) 0.06 1.4  (0.2) 1.3  (0.2) 1.6  (0.2) 1.6  (0.2) 0.30 
 
      
        
     
  
         
 
aAdjusted for age (age is unadjusted) 
 bNumbers in the analysis  for each variable differ slightly owing to missing values  
 cFEV1 = Forced expiratory volume in one second (adjusted for height)  
dsee methods section for definition 
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Table 2.  Hazard ratios (95% confidence intervals) for diabetes status  
in relation to cancer mortality in the Whitehall study 
 
Cancer outcomed Adjustment Number of deaths 
 
Hazard ratio (95% CI) P-value 
for trend 
  Normo-
glycaemic 
(N=16,843) 
IGT 
 
(N=975) 
NIDDM 
 
(N=188) 
Normo-
glycaemic 
IGT NIDDM  
         
All Cancers Age 2158 130 16 1.0 (ref) 1.03 (0.87, 1.23) 0.73 (0.44, 1.19) 0.58 
 Multiplea - - - 1.0 1.01 (0.84, 1.20) 0.74 (0.45, 1.20) 0.47 
Oesophagus Age 73 4 2 1.0 0.98 (0.36, 2.70) 3.00 (0.73,  12.3) 0.41 
 Multiple - - - 1.0 0.89 (0.32, 2.44) 3.02 (0.72, 12.6) 0.43 
Stomach Age 149 11 2 1.0 1.25 (0.68, 2.31) 1.26 (0.31, 5.09) 0.46 
 Multiple - - - 1.0 1.24 (0.67, 2.29) 1.24 (0.30, 5.03) 0.49 
Colon Age 193 11 1 1.0 0.97 (0.53, 1.79) 0.50 (0.07, 3.60) 0.61 
 Multiple - - - 1.0 0.95 (0.52, 1.76) 0.45 (0.06, 3.26) 0.52 
Rectum Age 73 2 0 1.0 0.43 (0.12,1.93)  0.0c 0.19 
 Multiple - - - 1.0 0.46 (0.11, 1.90)  0.0c 0.18 
Liver Age 31 4 3 1.0 2.47 (0.87, 7.03) 12.24 (3.68, 40.7) <0.001 
 Multiple - - - 1.0 1.91 (0.66, 5.49) 9.22 (2.66, 31.9) 0.001 
Pancreas Age 102 8 4 1.0 1.35 (0.66, 2.78) 3.88 (1.42, 10.7) 0.02 
 Multiple - - - 1.0 1.35 (0.66, 2.80) 3.99 (1.44, 11.0) 0.02 
Lung Age 647 34 2 1.0 0.86 (0.61, 1.21) 0.27 (0.07, 1.07) 0.05 
 Multiple - - - 1.0 0.83 (0.59, 1.18) 0.31 (0.08, 1.24) 0.06 
Prostate Age 240 14 0 1.0 1.00 (0.58, 1.72)  0.0c 0.34 
 Multiple - - - 1.0 1.05 (0.61, 1.81)  0.0c 0.47 
Bladder Age 84 11 0 1.0 2.25 (1.20, 4.23)  0.0c 0.16 
 Multiple - - - 1.0 2.19 (1.16, 4.16)  0.0c 0.15 
Kidney Age 46 3 0 1.0 1.17 (0.36, 3.76)  0.0c 0.83 
 Multiple - - - 1.0 1.10 (0.34, 3.56)  0.0c 0.80 
Brain Age 47 3 0 1.0 1.16 (0.36, 3.72)  0.0c 0.99 
 Multiple - - - 1.0 1.22 (0.38, 3.96)  0.0c 0.87 
Lymphoma Age 106 8 0 1.0 1.39 (0.68, 2.85)  0.0c 0.92 
 Multiple - - - 1.0 1.31 (0.63, 2.70)  0.0c 0.98 
Leukaemia Age 74 3 1 1.0 0.70 (0.22, 2.21) 1.32 (0.18, 9.55) 0.78 
 Multiple - - - 1.0 0.69 (0.22, 2.21) 1.28 (0.18, 9.37) 0.76 
Other cancers Age 293 14 1 1.0 0.86 (0.50, 1.47) 0.38 (0.05, 2.71) 0.30 
 Multiple - - - 1.0 0.82 (0.48, 1.40) 0.37 (0.05, 2.62) 0.23 
         
 
aAdjustment for confounding (age, employment grade, smoking status, physical activity, systolic blood pressure, blood 
pressure-lowering medication, marital status, disease at study entry, unexplained weight loss) and mediating (body mass 
index, triceps skinfold thickness, height adjusted FEV1, plasma cholesterol) variables. 
bsee methods section for definition 
c95% confidence interval could not be computed since the number of deaths was zero 
dcancer sub-types are ordered according to ascending ICD 8 code 
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Table 3.  Hazard ratios (95% confidence intervals) for diabetes status in relation to cancer 
mortality in the Whitehall study – excluding deaths occurring in the first 10 years of follow-up 
 
Cancer outcomed 
 
Adjustment Number of deaths Hazard ratio (95% CI) P-value  
for trend  
  Normo-
glycaemic 
(N=15, 231) 
IGT 
(N=815) 
NIDDM 
(N=132) 
Normo-
glycaemic 
IGT NIDDM  
         
All Cancers Age 1670 94 9 1.0 (ref) 1.01 (0.82, 1.24) 0.61 (0.32, 1.18) 0.38 
 Multiplea - - - 1.0 0.99 (0.80, 1.22) 0.63 (0.33, 1.22) 0.36 
Oesophagus Age 63 4 2 1.0 1.18 (0.43, 3.24) 3.86 (0.94, 15.9) 0.14 
 Multiple - - - 1.0 1.05 (0.38, 2.91) 4.00 (0.96, 16.7) 0.20 
Stomach Age 108 7 0 1.0 1.16 (0.54, 2.48)  0.0c 0.75 
 Multiple - - - 1.0 1.14 (0.53, 2.47)  0.0c 0.71 
Colon Age 148 6 1 1.0 0.73 (0.32, 1.64) 0.78 (0.11, 5.55) 0.45 
 Multiple - - - 1.0 0.70 (0.31, 1.60) 0.72 (0.10, 5.19) 0.40 
Rectum Age 55 2 0 1.0 0.64 (0.16, 2.64)  0.0c 0.37 
 Multiple - - - 1.0 0.61 (0.15, 2.53)  0.0c 0.33 
Liver Age 22 3 1 1.0 2.62 (0.78, 8.77) 6.17 (0.83, 46.1) 0.02 
 Multiple - - - 1.0 2.31 (0.68, 7.83) 4.74 (0.59, 37.9) 0.06 
Pancreas Age 78 6 2 1.0 1.38 (0.60, 3.17) 2.93 (0.72, 12.0) 0.13 
 Multiple - - - 1.0 1.41 (0.61, 3.25) 3.34 (0.81, 13.8) 0.10 
Lung Age 463 21 2 1.0 0.78 (0.50, 1.21) 0.45 (0.11, 1.81) 0.12 
 Multiple - - - 1.0 0.78 (0.50, 1.21) 0.54 (0.13, 2.16) 0.16 
Prostate Age 225 14 0 1.0 1.09 (0.63, 1.86)  0.0c 0.51 
 Multiple - - - 1.0 1.16 (0.67, 1.99)  0.0c 0.70 
Bladder Age 66 9 0 1.0 2.48 (1.24, 4.99)  0.0c 0.11 
 Multiple - - - 1.0 2.36 (1.16, 4.80)  0.0c 0.11 
Kidney Age 35 1 0 1.0 0.55 (0.08, 4.01)  0.0c 0.45 
 Multiple - - - 1.0 0.57 (0.08, 4.18)  0.0c 0.48 
Brain Age 19 2 0 1.0 2.01 (0.47, 8.66)  0.0c 0.60 
 Multiple - - - 1.0 2.09 (0.48, 9.16)  0.0c 0.54 
Lymphoma Age 89 6 0 1.0 1.25 (0.55, 2.87)  0.0c 0.93 
 Multiple - - - 1.0 1.20 (0.52, 2.77)  0.0c 0.87 
Leukaemia Age 56 2 0 1.0 0.62 (0.15, 2.56)  0.0c 0.35 
 Multiple - - - 1.0 0.60 (0.15, 2.48)  0.0c 0.32 
Other cancers Age 240 11 1 1.0 0.85 (0.46, 1.55) 0.52 (0.07, 3.67) 0.41 
 Multiple - - - 1.0 0.80 (0.43, 1.46) 0.50 (0.07, 3.59) 0.32 
         
 
aAdjustment for confounding (age, employment grade, smoking status, physical activity, systolic blood pressure, blood 
pressure-lowering medication, marital status, disease at study entry, unexplained weight loss) and mediating (body mass 
index, triceps skinfold thickness, height adjusted FEV1, plasma cholesterol) variables. 
bsee methods section for definition 
c95% confidence interval could not be computed since number of deaths was zero 
dcancer sub-types are ordered according to ascending ICD 8 code 
 
 
